AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16508777 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day)
Number of subjects: 29
Study 16508777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 14550687 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronavigated 1 Hz rTMS
Number of subjects: 3
Study 14550687 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 3
Study 11418517 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution 100 mg bd
Number of subjects: 277
Study 11418517 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B 500 mg tds plus nystatin 2 MU qds
Number of subjects: 277
Study 9596317 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional medical therapy plus NPPV
Number of subjects: 27
Study 9596317 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy alone
Number of subjects: 27
Study 8042719 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol/fentanyl (4-8 mg.kg‐1.h‐1, 1.2 mg.h‐1)
Number of subjects: 30
Study 8042719 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane/fentanyl (0.6-1.2 vol%, 1.2 mg.h‐1)
Number of subjects: 30
Study 8042719 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam/fentanyl (1.2 mg.h‐1)
Number of subjects: 30
Study 8042719 — intervention group
Group type: COMPARATOR
Intervention: surgical stimulation (skin incision, sternotomy)
Number of subjects: 30
Study 2847928 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.45 mg daily for three days
Number of subjects: 45
Study 7938559 — intervention group
Group type: EXPERIMENTAL
Intervention: SC 48,274 1mg
Number of subjects: 65
Study 7938559 — intervention group
Group type: EXPERIMENTAL
Intervention: SC 48,274 25mg
Number of subjects: 65
Study 7938559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 84148 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (800 mg daily)
Number of subjects: 120
Study 84148 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine (2 g daily)
Number of subjects: 120
Study 84148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of disodium cromoglycate and sulphasalazine
Number of subjects: 120
Study 30671722 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved solid fuel stoves and clean cooking options (LPG and induction stoves)
Number of subjects: 0
Study 30671722 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatments (stove exchanges and free stoves)
Number of subjects: 0
Study 30671722 — intervention group
Group type: EXPERIMENTAL
Intervention: Free stoves
Number of subjects: 0
Study 29735484 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 200 mg single-dose
Number of subjects: 501
Study 29735484 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg 2-dose
Number of subjects: 501
Study 29735484 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 500 mg single-dose
Number of subjects: 501
Study 29735484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 26822398 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus vinorelbine (40 mg/day afatinib + 25 mg/m² vinorelbine per week)
Number of subjects: 508
Study 26822398 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus vinorelbine (2 mg/kg trastuzumab per week after 4 mg/kg loading dose + 25 mg/m² vinorelbine per week)
Number of subjects: 508
Study 26822398 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus vinorelbine
Number of subjects: 508
Study 25707822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical method (specific toothbrush and dentifrice)
Number of subjects: 30
Study 25707822 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical method (2% R. communis solution)
Number of subjects: 30
Study 25707822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined method (Mechanical + Chemical)
Number of subjects: 30
Study 22594388 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School (active therapy, ergonomics, and education)
Number of subjects: 124
Study 22594388 — intervention group
Group type: COMPARATOR
Intervention: Passive physiotherapy (control)
Number of subjects: 124
Study 18834700 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workshop consisting of eight 180-minute training sessions over four months
Number of subjects: 40
Study 18834700 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 40
Study 17878765 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic application of ACh
Number of subjects: 40
Study 17878765 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic application of SNP
Number of subjects: 40
Study 15084209 — intervention group
Group type: EXPERIMENTAL
Intervention: Edited alpha1
Number of subjects: 40
Study 15084209 — intervention group
Group type: EXPERIMENTAL
Intervention: Unedited alpha1
Number of subjects: 40
Study 15084209 — intervention group
Group type: EXPERIMENTAL
Intervention: Unedited alpha1 in general population
Number of subjects: 40
Study 15084209 — intervention group
Group type: COMPARATOR
Intervention: Alpha1 reduction due to premature beats
Number of subjects: 40
Study 11965272 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia and postoperative epidural analgesia for 72 hours with general anaesthesia
Number of subjects: 915
Study 11965272 — intervention group
Group type: COMPARATOR
Intervention: Control (alternative analgesic regimens with general anaesthesia)
Number of subjects: 915
Study 11965272 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 915
Study 11965272 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia
Number of subjects: 915
Study 9701893 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncooked rice ORS
Number of subjects: 70
Study 9701893 — intervention group
Group type: COMPARATOR
Intervention: WHO-ORS
Number of subjects: 70
Study 7907893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 7907893 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine
Number of subjects: 0
Study 2698241 — intervention group
Group type: EXPERIMENTAL
Intervention: Optrex Eye Lotion (self-administered by irrigation into the left eye three times daily for seven days)
Number of subjects: 24
Study 2698241 — intervention group
Group type: EXPERIMENTAL
Intervention: Optrex Eye Lotion (self-administered in the right eye by 15 patients)
Number of subjects: 24
Study 2698241 — intervention group
Group type: EXPERIMENTAL
Intervention: Optrex Eye Lotion
Number of subjects: 24
Study 183554 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (750 mg three times daily for 5 days)
Number of subjects: 115
Study 183554 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (1 g twice daily on 2 consecutive days)
Number of subjects: 115
Study 183554 — intervention group
Group type: COMPARATOR
Intervention: Starch placebo
Number of subjects: 115
Study 31418168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 101
Study 31418168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 31418168 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 101
Study 28328234 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL)
Number of subjects: 0
Study 28328234 — intervention group
Group type: COMPARATOR
Intervention: Human insulin (HI)
Number of subjects: 0
Study 25354751 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (10 Hz stimulation of the bilateral dorsolateral prefrontal cortex for 3 weeks)
Number of subjects: 32
Study 25354751 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 32
Study 25354751 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 32
Study 23857221 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1.5-2.5 g per day)
Number of subjects: 52
Study 23857221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 20528207 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus low-dose oral contraceptive (ethinyl oestradiol-cyproterone acetate, EE/CA) 850 mg metformin twice a day for three cycles
Number of subjects: 60
Study 20528207 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-PCOS subjects)
Number of subjects: 60
Study 19423131 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam and investigational compound
Number of subjects: 211
Study 19423131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 16412864 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing at 75 beats/min
Number of subjects: 15
Study 16412864 — intervention group
Group type: COMPARATOR
Intervention: Control (pacing turned off)
Number of subjects: 15
Study 15255788 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (5 micro g kg(‐1) min(‐1))
Number of subjects: 14
Study 15255788 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% glucose solution)
Number of subjects: 14
Study 10675425 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 19
Study 9411510 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbo STIR (T-STIR) sequence
Number of subjects: 20
Study 9411510 — intervention group
Group type: COMPARATOR
Intervention: Conventional STIR sequence
Number of subjects: 20
Study 8244916 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 micrograms formoterol
Number of subjects: 13
Study 8244916 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol
Number of subjects: 13
Study 8244916 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms salbutamol
Number of subjects: 13
Study 3516608 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 231
Study 3516608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 29273827 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol (ELD; 0.75 μg/day)
Number of subjects: 40
Study 29273827 — intervention group
Group type: EXPERIMENTAL
Intervention: 1α hydroxyl calcidiol (ALF; 1 μg/day)
Number of subjects: 40
Study 29273827 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain vitamin D3 (800 IU/day)
Number of subjects: 40
Study 29273827 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 28167659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg orally once daily until progression or unacceptable toxicity
Number of subjects: 63
Study 28167659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 63
Study 26272523 — intervention group
Group type: EXPERIMENTAL
Intervention: High mean SAI QRST (third tertile)
Number of subjects: 234
Study 23679113 — intervention group
Group type: EXPERIMENTAL
Intervention: Live induction
Number of subjects: 39
Study 23679113 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded induction
Number of subjects: 39
Study 23679113 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 21446892 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 1385
Study 21446892 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 80 mg
Number of subjects: 1385
Study 21446892 — intervention group
Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 1385
Study 17938986 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 759
Study 17938986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 759
Study 16542484 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP/norepinephrine
Number of subjects: 18
Study 16542484 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine alone
Number of subjects: 18
Study 12802880 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg)
Number of subjects: 20
Study 10806607 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg)
Number of subjects: 9
Study 10806607 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg)
Number of subjects: 9
Study 10806607 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg) and Metoprolol (50 mg) together
Number of subjects: 9
Study 10806607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10180860 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D injection
Number of subjects: 100000
Study 10180860 — intervention group
Group type: COMPARATOR
Intervention: Calcitonin
Number of subjects: 100000
Study 1710921 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP-ABVD alternating regimen (monthly alternating one cycle of MOPP and one cycle of ABVD)
Number of subjects: 300
Study 1710921 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPP-ABVD hybrid regimen (one half cycle of MOPP alternated with one half cycle of ABVD within a one-month period)
Number of subjects: 300
Study 6128673 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic desensitization
Number of subjects: 60
Study 6128673 — intervention group
Group type: COMPARATOR
Intervention: Counseling
Number of subjects: 60
Study 6128673 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 60
Study 31596119 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 standardisation
Number of subjects: 382
Study 31596119 — intervention group
Group type: COMPARATOR
Intervention: Group 2 validation
Number of subjects: 382
Study 27696324 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive response generation
Number of subjects: 731
Study 25510926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Enhancement Therapy (CET)
Number of subjects: 31
Study 25510926 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study 23022092 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction-only group (multimedia presentation)
Number of subjects: 27
Study 23022092 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (multimedia presentation and real-time visual feedback)
Number of subjects: 27
Study 23022092 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 27
Study 22137863 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with TGHP (iodine-based tetraglycine hydroperiodide)
Number of subjects: 60
Study 22137863 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with CD (chlorine dioxide)
Number of subjects: 60
Study 22137863 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with TGHP plus ascorbic acid
Number of subjects: 60
Study 22137863 — intervention group
Group type: EXPERIMENTAL
Intervention: Water alone
Number of subjects: 60
Study 22137863 — intervention group
Group type: EXPERIMENTAL
Intervention: Water with CD plus ascorbic acid
Number of subjects: 60
Study 19638454 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 230
Study 19638454 — intervention group
Group type: COMPARATOR
Intervention: MTX and SSZ combination therapy
Number of subjects: 230
Study 19638454 — intervention group
Group type: COMPARATOR
Intervention: MTX-SSZ group
Number of subjects: 230
Study 16990992 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human MBL (rhMBL) 0.01, 0.05, 0.1, and 0.5 mg/kg single intravenous infusions
Number of subjects: 0
Study 16990992 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human MBL (rhMBL) 0.1 or 0.3 mg/kg repeated intravenous infusions at 3-day intervals
Number of subjects: 0
Study 16990992 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human MBL (rhMBL) 0.5 mg/kg single intravenous infusion
Number of subjects: 0
Study 16990992 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human MBL (rhMBL)
Number of subjects: 0
Study 16990992 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 15502290 — intervention group
Group type: EXPERIMENTAL
Intervention: Job specific training
Number of subjects: 30
Study 15502290 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic body mechanic training (BBMT)
Number of subjects: 30
Study 15502290 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 11046206 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (4 puffs, 15-20 min before intubation)
Number of subjects: 60
Study 11046206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg, 3 min before intubation)
Number of subjects: 60
Study 8375519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular hCG (10,000 IU)
Number of subjects: 30
Study 8375519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hCG (500 IU)
Number of subjects: 30
Study 3018822 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (22 micrograms/kg)
Number of subjects: 10
Study 3018822 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (11 micrograms/kg)
Number of subjects: 10
Study 3018822 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine (0.5 mg)
Number of subjects: 10
Study 3018822 — intervention group
Group type: EXPERIMENTAL
Intervention: Methscopolamine (0.75 mg)
Number of subjects: 10
Study 3018822 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (22 micrograms/kg) with scopolamine
Number of subjects: 10
Study 30107400 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative trial designs and analytical methods for randomized clinical trials
Number of subjects: 0
Study 30107400 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic and pharmacodynamic modeling
Number of subjects: 0
Study 30107400 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitive primary end points
Number of subjects: 0
Study 30107400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical nested-trial designs
Number of subjects: 0
Study 30107400 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian methods and/or platform trials
Number of subjects: 0
Study 25854535 — intervention group
Group type: COMPARATOR
Intervention: Exercise-based PE
Number of subjects: 767
Study 25854535 — intervention group
Group type: COMPARATOR
Intervention: Games-based PE
Number of subjects: 767
Study 24557728 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 224
Study 24557728 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 224
Study 22999808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide/salbutamol sulfate (500 μg/2.5 mg) combination
Number of subjects: 37
Study 22999808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl)
Number of subjects: 37
Study 20691306 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EESs)
Number of subjects: 109
Study 20691306 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PESs)
Number of subjects: 109
Study 18294310 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alitretinoin 10 mg once daily for up to 24 weeks
Number of subjects: 1032
Study 18294310 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alitretinoin 30 mg once daily for up to 24 weeks
Number of subjects: 1032
Study 18294310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1032
Study 15783281 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivationally based intervention (MBI)
Number of subjects: 73
Study 15783281 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control (AC)
Number of subjects: 73
Study 12637478 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cycles of BEP chemotherapy (bleomycin, etoposide, cisplatin) over 5 days
Number of subjects: 666
Study 12637478 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 cycles of BEP chemotherapy (bleomycin, etoposide, cisplatin) over 3 days
Number of subjects: 666
Study 10471647 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-Trac II ELISA
Number of subjects: 0
Study 8611382 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (600 mg m‐2) administered every 3 weeks for three courses with prednisone and interferon‐alpha2b
Number of subjects: 83
Study 8611382 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (70 mg m‐2) administered every 3 weeks for three courses with prednisone and interferon‐alpha2b
Number of subjects: 83
Study 1416333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized saline canister (220 mL saline at 8 psi)
Number of subjects: 550
Study 1416333 — intervention group
Group type: COMPARATOR
Intervention: Syringe irrigation (250 mL saline)
Number of subjects: 550
Study 1416333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized saline canister
Number of subjects: 550
Study 1416333 — intervention group
Group type: COMPARATOR
Intervention: Syringe irrigation
Number of subjects: 550
Study 4074604 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol 1 mg
Number of subjects: 14
Study 4074604 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol 8 mg
Number of subjects: 14
Study 4074604 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproterol (various doses)
Number of subjects: 14
Study 29602338 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary use of an intraoral vibrational device (AcceleDent; 20 minutes/day) (n=29)
Number of subjects: 81
Study 29602338 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical nonfunctional (sham) device (n=25)
Number of subjects: 81
Study 29602338 — intervention group
Group type: COMPARATOR
Intervention: Fixed-appliance only (n=27)
Number of subjects: 81
Study 27990219 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with Nordic poles
Number of subjects: 20
Study 27990219 — intervention group
Group type: COMPARATOR
Intervention: Walking without Nordic poles
Number of subjects: 20
Study 24131826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics (galacto‐oligosaccharide and polydextrose mixture, 1:1)
Number of subjects: 94
Study 24131826 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG, ATCC 53103)
Number of subjects: 94
Study 24131826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose)
Number of subjects: 94
Study 24131826 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotics
Number of subjects: 94
Study 24131826 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 94